Ebb D H, Weinstein H J
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Pediatr Clin North Am. 1997 Aug;44(4):847-62. doi: 10.1016/s0031-3955(05)70533-2.
Acute myelogenous leukemia (AML) accounts for about 20% of the acute leukemias seen in children. In contrast to childhood acute lymphoblastic leukemia (ALL), there has only been a modest improvement in the cure rate of children with AML during the past two decades. Approximately 40% of children treated with chemotherapy alone are long-term survivors. The outcome is somewhat better for those children who are given bone marrow transplants from histocompatible sibling donors early in the first remission. During the last decade, however, new insights into the molecular basis of AML has increased our understanding of the pathogenesis and biology of this group of leukemias and are beginning to provide us with new therapeutic strategies.
急性髓性白血病（AML）约占儿童急性白血病的20%。与儿童急性淋巴细胞白血病（ALL）不同，在过去二十年中，儿童AML的治愈率仅有适度提高。仅接受化疗的儿童中约40%为长期存活者。对于那些在首次缓解早期接受来自组织相容性同胞供体的骨髓移植的儿童，其预后稍好。然而，在过去十年中，对AML分子基础的新认识增进了我们对这组白血病发病机制和生物学的理解，并开始为我们提供新的治疗策略。
